CARsgen Expands CAR-T Manufacturing Base through New Strategic Partnerships in Shanghai CARsgen Therapeutics is enhancing its CAR-T product capabilities by signing agreements in Shanghai, ensuring future growth in the biopharmaceutical sector.

CARsgen Expands CAR-T Manufacturing Base through New Strategic Partnerships in Shanghai #China #Shanghai #CAR-T #CARsgen

⚡️ #CARsgen soumet des applications IND doubles pour le produit #Allogène 💉 #BCMA #CAR_T 🧬 #CT0596

Les demandes visent deux essais cliniques pour le traitement du #MyélomeMultiple 🩸 (R/R) & de la #Leucémie 🩸 des cellules plasmocytaires primaires ( #pPCL)
www.prnewswire.com/news-release...

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it...

⚡️ #CARsgen a soumis deux demandes d' #IND auprès de la #NMPA pour son produit #Allogénique ciblant #BCMA avec cellules #CAR_T 🧬, #CT0596
Les demandes visent à initier deux essais cliniques de phase Ib/II pour le #MyélomeMultiple R/R et de la #Leucémie #pPCL
www.prnewswire.com/news-release...

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that...

⚡️ #CARsgen 🇨🇳 annonce les données de la thérapie #Allogénique 💉 par cellules #BCMA #CAR_T 🧬 #CT0596 pour le #MyélomeMultiple 🩸 R/R lors de la réunion annuelle de l’ #ASH2025
www.prnewswire.com/news-release...

CARsgen Presents Promising Results for Allogeneic CAR-T Therapy at ASH Annual Meeting 2025 CARsgen Therapeutics reveals encouraging clinical data for CT0596, a novel allogeneic CAR-T therapy for multiple myeloma, at ASH 2025.

CARsgen Presents Promising Results for Allogeneic CAR-T Therapy at ASH Annual Meeting 2025 #China #Shanghai #CAR-T_therapy #CARsgen #CT0596

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces...

✨ #CARsgen annonce des données positives pour les produits #CAR_T 🧬 #Allogéniques #CT0596 ciblant #BCMA pour le #MyélomeMultiple 🩸 R/R, et pour #CT1190B, un produit candidat CAR-T allogénique ciblant #CD19/#CD20 pour le #Lymphome 🩸 non hodgkinien #LNH R/R.
www.prnewswire.com/news-release...

CARsgen Therapeutics Shows Promising Results for Satri-cel in Pancreatic Cancer Treatment at ESMO 2025 CARsgen's novel Satri-cel therapy has demonstrated preliminary effectiveness in treating pancreatic cancer, as highlighted at ESMO Congress 2025.

CARsgen Therapeutics Shows Promising Results for Satri-cel in Pancreatic Cancer Treatment at ESMO 2025 #China #Shanghai #pancreatic_cancer #CARsgen #Satri-cel

New CAR-T Therapy CT0596 Shows Promise for Treating Primary Plasma Cell Leukemia CARsgen's CT0596, an allogeneic BCMA CAR-T therapy, shows promise in treating relapsed/refractory primary plasma cell leukemia, offering hope for patients.

New CAR-T Therapy CT0596 Shows Promise for Treating Primary Plasma Cell Leukemia #China #Shanghai #CARsgen #CT0596 #pPCL

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

✨ #CARsgen présente les résultats du #CT071 ( #CAR_T 🧬 autologue ciblant #GPRC5D) pour le traitement du #MyélomeMultiple 🩸 R/R dans le cadre d’un essai initié par l’investigateur ( #NCT05838131) ont été publiés dans "The Lancet Haematology 🩸"
www.prnewswire.com/news-release...

CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma CARsgen Therapeutics has revealed encouraging results for its CT071 CAR T-cell therapy targeting GPRC5D in patients with relapsed/refractory multiple myeloma, documented in The Lancet.

CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma #China #Shanghai #CAR-T #CARsgen #GPRC5D

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

✨ #CARsgen présente les résultats du suivi à LT de #Zevor_cel 🧬 à l’ #IMS25

Dans l'étude 14 patients atteints d’un #MyélomeMultiple 🩸 R/R

Taux de réponse de 100 % (IC à 95 % : 76,8, 100,0) avec 11 (78,6 %) patients obtenant une réponse complète (RC)

www.prnewswire.com/news-release...

CARsgen's Latest Findings on Zevor-cel at IMS 2025 Highlight Efficacy and Safety in Treating Multiple Myeloma The new long-term follow-up results for Zevor-cel, presented by CARsgen at IMS 2025, reveal promising efficacy and safety data for multiple myeloma patients.

CARsgen's Latest Findings on Zevor-cel at IMS 2025 Highlight Efficacy and Safety in Treating Multiple Myeloma #China #Shanghai #Multiple_Myeloma #CARsgen #Zevor-cel

CARsgen Therapeutics Announces 2025 Interim Results /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its...

⚡️ #CARsgen annonce ses résultats intermédiaires pour 2025

Plusieurs produits #CAR_T 🧬 #Allogéniques sont en cours de développement, couvrant des domaines de traitement tels que les hémopathies malignes, les #TumeursSolides et les maladies auto-immunes
www.prnewswire.com/news-release...

CARsgen Therapeutics Reports Strong Interim Results for 2025 with Innovations in CAR T-Cell Therapies CARsgen Therapeutics has unveiled its 2025 interim results, showcasing advancements in CAR T-cell therapies and revealing promising financial growth and product development.

CARsgen Therapeutics Reports Strong Interim Results for 2025 with Innovations in CAR T-Cell Therapies #China #Shanghai #CARsgen #Satri-cel #Zevor-cel

CARsgen Therapeutics Achieves Victory in GPC3 CAR-T Patent Dispute at EPO CARsgen Therapeutics has successfully defended its GPC3 CAR-T patent at the European Patent Office, enhancing its position in innovative cancer therapies.

CARsgen Therapeutics Achieves Victory in GPC3 CAR-T Patent Dispute at EPO #China #Shanghai #CARsgen #GPC3_CAR-T #European_Patent

CARsgen Therapeutics Secures Priority Review for Satri-cel in China CARsgen Therapeutics has received Priority Review for its CAR T-cell therapy, Satri-cel, targeting advanced gastric cancer in patients with limited treatment options.

CARsgen Therapeutics Secures Priority Review for Satri-cel in China #China #Shanghai #CARsgen #Satri-cel #T-Cell_Therapy

CARsgen's Breakthrough CAR T-Cell Therapy Shows Promise for Advanced Gastric Cancer CARsgen Therapeutics has released significant data on its CAR T-cell therapy, satricabtagene autoleucel, for advanced gastric cancer, available on the ASCO website.

CARsgen's Breakthrough CAR T-Cell Therapy Shows Promise for Advanced Gastric Cancer #China #Shanghai #CARsgen #Satri-cel #G/GEJC

CARsgen's CT0596 Shows Encouraging Results in Preliminary Clinical Trials for BCMA CAR-T Therapy CARsgen Therapeutics announces preliminary clinical data for CT0596, indicating its potential effectiveness and safety in treating relapsed multiple myeloma.

CARsgen's CT0596 Shows Encouraging Results in Preliminary Clinical Trials for BCMA CAR-T Therapy #China #Shanghai #CAR-T_therapy #CARsgen #CT0596

CARsgen Therapeutics Reports Promising Developments in 2024 Annual Results for CAR T-Cell Innovations Explore CARsgen's recent advancements in CAR T-cell therapy with 2024 annual results showcasing significant milestones and future plans.

CARsgen Therapeutics Reports Promising Developments in 2024 Annual Results for CAR T-Cell Innovations #China #Shanghai #CARsgen #Satri-cel #Zevor-cel

CARsgen's Breakthrough Therapy Designation for Claudin18.2 CAR-T Therapy Brings Hope for Cancer Treatment CARsgen Therapeutics has received Breakthrough Therapy Designation for their Claudin18.2 CAR-T therapy, satri-cel, set to aid advanced gastric cancer patients.

CARsgen's Breakthrough Therapy Designation for Claudin18.2 CAR-T Therapy Brings Hope for Cancer Treatment #China #Shanghai #CARsgen #Satri-cel #Claudin18.2

Innovative CD19/CD20 CAR-T Therapy Marks Milestone for Autoimmune Disease Treatment CARsgen's latest allogeneic CD19/CD20 CAR-T therapy has successfully administered its first dose to a lupus patient, showing promise in autoimmunity treatment.

Innovative CD19/CD20 CAR-T Therapy Marks Milestone for Autoimmune Disease Treatment #China #Shanghai #CARsgen #KJ-C2219 #THANK-u_Plus

CARsgen's Innovative CAR-T Therapy Shows Promising Results in Clinical Trial for Multiple Myeloma CARsgen Therapeutics announces significant achievements in a CAR-T clinical trial for multiple myeloma, showcasing their innovative approach to cancer therapy.

CARsgen's Innovative CAR-T Therapy Shows Promising Results in Clinical Trial for Multiple Myeloma #China #Shanghai #CAR-T_therapy #CARsgen #THANK-u_Plus

CARsgen Launches Investigator-Initiated Trial for CAR-T Therapy Targeting CD19/CD20 CARsgen Therapeutics has begun an investigator-initiated trial in China for KJ-C2219, an allogeneic CAR-T therapy aimed at battling B-cell non-Hodgkin lymphoma.

CARsgen Launches Investigator-Initiated Trial for CAR-T Therapy Targeting CD19/CD20 #China #Shanghai #CAR-T_therapy #CARsgen #KJ-C2219

CARsgen's Groundbreaking Phase II Results for Claudin18.2 CAR-T Therapy Bring Hope to Cancer Patients CARsgen's latest clinical trial reveals positive results for satricabtagene autoleucel, paving the way for innovative gastric cancer treatment.

CARsgen's Groundbreaking Phase II Results for Claudin18.2 CAR-T Therapy Bring Hope to Cancer Patients #China #Shanghai #CARsgen #Satri-cel #Claudin18.2